外科甲状腺学年度回顾:近期技术进展与未来挑战
本文综述2020年9月1日至2021年8月1日发表的外科与介入甲状腺学技术进展,涵盖连续术中神经监测、甲状旁腺自体荧光、经口腔前庭入路甲状腺切除术及射频消融。连续术中神经监测较间歇监测降低术后声带麻痹风险,甲状旁腺自体荧光诊断比值比达228.9,经口腔前庭入路与经颈入路主要并发症无显著差异,射频消融治疗良性结节和微小乳头状癌显示一定效果,但作者指出需进一步严格研究明确其效用与价值。
要点
- 甲状旁腺自体荧光检测甲状旁腺的诊断比值比为228.9,敏感性96%、特异性92%。
- 经口腔前庭入路与经颈甲状腺切除术主要并发症发生率无显著差异(1.5% vs 2.1%,p=0.75)。
核心结论
- 连续术中神经监测、甲状旁腺自体荧光、经口腔前庭入路甲状腺手术及射频消融是甲状腺疾病管理的最新工具,显示改善预后、减少并发症和提高生活质量的希望,但需进一步严格研究明确其效用与价值。
研究设计与样本
- 本文为综述,检索2020年9月1日至2021年8月1日发表的外科与介入甲状腺学技术发展方面最有影响力的文章,检索三个电子数据库并咨询专家。
主要发现
- 甲状旁腺自体荧光检测甲状旁腺较肉眼识别诊断比值比为228.9,敏感性96%、特异性92%。
- 经口腔前庭入路甲状腺切除术与经颈甲状腺切除术主要并发症发生率无显著差异(1.5% vs 2.1%,p=0.75);超重组累积并发症比值比OR=0.52(95%CI 0.17-1.58),肥胖组OR=1.69(95%CI 0.74-3.88)。
- 射频消融治疗良性甲状腺结节通常导致体积缩小50-85%,治疗后15个月较传统甲状腺切除术恢复更快、疼痛更少、社会心理健康更好,但传统手术组身体健康水平更高。
- 射频消融治疗微小乳头状癌与经颈叶切除术相比,局部肿瘤进展(1.8% vs 3.3%,p=0.209)、淋巴结转移(0.6% vs 0.6%,p=1.000)、复发(1.2% vs 2.4%,p=0.244)及4年无复发生存率(98.2% vs 97.0%,p=0.223)均无显著差异。
临床怎么用
- 作者认为连续术中神经监测、甲状旁腺自体荧光、经口腔前庭入路甲状腺手术及射频消融是甲状腺疾病管理的最新工具,显示改善预后、减少并发症和提高生活质量的希望,但需进一步严格研究明确其效用与价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The field of surgical and interventional thyroidology is rapidly evolving. In the past few years, we have seen the introduction and establishment of many novel surgical adjuncts, techniques, and disruptive ablative technologies that have impacted the field. Methods: We identified the most influential articles on technological developments in surgical and interventional thyroidology that were published from September 1, 2020, to August 1, 2021. We searched three electronic databases and consulted experts. Results: Major findings are summarized. Continuous intraoperative nerve monitoring (cIONM) lowered the risk of early postoperative vocal cord palsy 1.8-fold and permanent palsy 29 · 4-fold compared with intermittent intraoperative nerve monitoring. Parathyroid autofluorescence yielded a diagnostic odds ratio (OR) of 228.9 for detection of parathyroid glands over visualization, with 96% sensitivity and 92% specificity. There was no significant difference in the incidence of major complications between the transoral endoscopic thyroidectomy vestibular approach (TOETVA) and transcervical thyroidectomy (1.5% vs. 2.1%, p = 0.75), and a higher body mass index did not lead to a significant increase in the odds of cumulative complication with TOETVA for the overweight (OR = 0.52 [95% confidence interval {CI} 0.17-1.58]) and obese groups (OR = 1.69 [CI 0.74-3.88]). Radiofrequency ablation (RFA) for benign thyroid nodules typically resulted in a 50-85% volume reduction with faster recovery times, less pain levels, and higher social and psychological well-being compared with conventional thyroidectomy at 15 months post-treatment, although physical well-being levels were higher in the conventional thyroidectomy group at this time. RFA for papillary thyroid microcarcinoma showed no significant difference in local tumor progression (1.8% vs. 3.3%, p = 0.209), lymph node metastasis (0.6% vs. 0.6%, p = 1.000), recurrence (1.2% vs. 2.4%, p = 0.244), and 4-year recurrence-free survival rates (98.2% vs. 97.0%, p = 0.223) when compared with transcervical lobectomy. Conclusions: cIONM, parathyroid autofluorescence, transoral vestibular approach thyroid surgery, and RFA for benign and malignant thyroid nodules are some of the latest additions to the surgeon's and interventionalist's armamentarium to manage thyroid disease. These technological advancements demonstrate promise to improve outcomes, decrease complications, and enhance a patient's quality of life, but further rigorous studies are needed to define their utility and value.
引用
- Tufano RP, Mohamed Ali K. The Year in Surgical Thyroidology: Recent Technological Developments and Future Challenges. Thyroid. 2022. PMID: 34915767. doi:10.1089/thy.2021.0590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。